ABSTRACT: Introduction: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS). Methods: We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale-Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting. Results: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerated with no serious adverse events. Discussion: Rasagiline did not alter disease progression compared with controls over 12 months of treatment.
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with a median survival of approximately 2 years. 1 Despite dozens of trials over the last 20 years, only 2 drugs have received United States Food and Drug Administration approval, riluzole and edaravone, which have modest benefits on survival or disease progression. [2] [3] [4] There is an urgent need for new therapies. More recent attempts to improve the yield of clinical trials have centered on developing biomarkers to show early drug-target engagement or use of large data sets from previous clinical trials to improve trial efficiency. [5] [6] [7] Mitochondrial dysfunction leads to downstream ALS pathological features, including oxidative stress and protein misfolding and aggregation. [8] [9] [10] Many genetic mutations in familial ALS affect enzymes, with key roles in mitochondrial function. 11 Rasagiline is a monoamine oxidase type B (MAO-B) inhibitor approved for symptomatic treatment of Parkinson's disease, with a well-defined safety profile. In vitro studies in neuronal cell cultures and in vivo studies in animal models of central neuronal damage have suggested a neuroprotective role for rasagiline mediated by antioxidative or antiapoptotic actions. [12] [13] [14] [15] [16] Arguments supporting the use of rasagiline in ALS include: autopsy studies suggesting MAO-B is upregulated in ALS tissues 13, 17, 18 ; increased survival in an ALS animal model 19 ; and a retrospective case series in humans suggesting slowing of functional loss. 20 Our earlier open-label study of rasagiline in ALS, while not showing improved function vs. historical controls, showed evidence for drug-target engagement in mitochondrial biomarkers. 21 Herein we tested whether rasagiline could slow disease progression and engaged mitochondrial biomarkers over 12 months of treatment.
METHODS
Trial Design. We performed a 12-month randomized, double-blind, placebo-controlled study enriched with historical placebo controls at 10 sites in the United States between November 2012 and August 2017. The trial was approved by institutional review boards at each site. Written informed consent was obtained from all participants, in accordance with the Declaration of Helsinki and the principles of good clinical practice. This study has been registered at clinicaltrials.gov (NCT01786603). A data safety monitoring board met quarterly by phone to review adverse events and serious adverse events.
Participants were 21-80 years of age; had laboratorysupported probable, probable, or definite ALS by El Escorial criteria; had a slow or forced vital capacity (FVC) of ≥ 75% predicted; and had onset of symptoms within 2 years of enrollment. 22 Women with child-bearing potential had to be using an effective means of birth control. Participants were excluded if they required tracheostomy or noninvasive ventilation; had a diaphragmatic pacemaker; received an experimental drug within the last 30 days; were taking medications contraindicated for use with rasagiline (sympathomimetic agents, analgesics with serotoninergic properties, fluoxetine, or fluvoxamine, or taking larger doses of antidepressants with serotoninergic properties); had a diagnosis of other neurodegenerative disease; were currently pregnant or breastfeeding; had a history of recent substance abuse; demonstrated noncompliance with a previous clinical study; or had an unstable medical illness.
The trial was conducted by the Western ALS Study Group (WALS) at 10 academic centers in the United States (see Appendix in Supplementary Material available online). Data coordinating was done through the Muscle Study Group at the University of Rochester Medical Center.
Rasagiline was provided by TEVA Pharmaceuticals. Rasagiline and placebo were overencapsulated by the University of Iowa's Research Pharmacy, using identical gelatin capsules.
Outcomes and Measures. Baseline characteristics included sex, age, and self-reported race/ethnicity. The ALS Functional Rating Scale-Revised (ALSFRS-R), the slow vital capacity, the global ALS Quality of Life (ALSQOL) question, and adverse events were assessed at baseline and monthly for 2 months, then every other month for a total of 12 months. If a subject was unable to attend a study visit, the ALSFRS-R was performed by telephone. Evaluators at each site were trained at study start-up in administration of the ALSFRS-R and slow vital capacity. Blood and urine for biomarkers were collected at baseline and at months 6 and 12, except for transactive response DNA binding protein 43 kDa (TDP-43), which was collected at baseline and month 12.
The primary outcome for the study was the difference in the average monthly slope of decline over 12 months of the ALSFRS-R between treated and untreated patients (plus historical controls). 23 Changes in the ALSFRS-R predict survival, and a change of >20% in the slope of decline is considered clinically meaningful. 24 Secondary Outcomes. The slow vital capacity is used widely in ALS clinical trials, and for most individuals is virtually identical to the forced vital capacity. 25 The baseline vital capacity and decline in vital capacity are both predictors of survival. 26, 27 The single-item ALSQOL asks the participant to rank their global quality of life, taking into account physical, emotional, social, spiritual, and financial aspects of living, and is ranked from 0 (very bad) to 10 (excellent). 28 For survival analysis, we defined mortality as death or use of invasive mechanical ventilation.
Exploratory Outcomes. In an earlier study, we showed that, when using commercially available assays of mitochondrial membrane stability or apoptosis, administration of rasagiline appeared to increase mitochondrial membrane potential, decrease oxidative stress, and increase the ratio of anti-to proapoptotic proteins. 21 Several mitochondrial assays were completed using lymphocytes, including 2 measures of lymphocyte mitochondrial membrane potential: JC-1 (MitoProbe JC-1 Assay Kit for Flow Cytometry; Invitrogen/Thermo Fisher Scientific, Waltham, Massachusetts) 29 and Mitotracker Red CMXRos (Vybrant Apoptotic Assay Kit #11; Molecular Probes, Eugene, Oregon) 30 ; and a measure of apoptosis, dye-conjugated Annexin V stain, in which the amount of exposed phosphatidylserine was approximated by calculating the percentage of annexin-positive cells (see Table S2 in Supplementary Material Methods for a list of all biomarkers reported in this study). 31 Bcl-2 and Bax messenger RNA ratios were determined from whole blood, providing information about a cell or tissue's relative state of apoptosis activity 32 ; and a measurement was undertaken of free radical stress from plasma via an oxygen radical antioxidant capacity assay (ORAC; OxiSelect ORAC Activity Assay; Cell Biolabs, San Diego, California). 33 The primary biomarker analysis was performed on 6-month change, due to early termination affecting the 12-month time-point.
In urine, levels of 15-F2t-isoprostane (IsoP), a lipid peroxidation product, reflect oxidative stress. We used a validated, commercially available assay for IsoP that members of our team showed were increased in urine in a previous ALS study (8-isoPGF2a ELISA Kit; Detroit R&D, Detroit, Michigan). 34 Frontotemporal lobar degeneration and ALS are both marked by nuclear exclusion and cytoplasmic deposition of TDP-43, which is considered a pathological hallmark of both disorders. 35, 36 Plasma TDP-43, as measured by enzyme-linked immunoassay (ELISA), has been proposed as a possible biomarker for Alzheimer's disease and frontotemporal dementia (FTD), with elevations in individuals with Alzheimer's disease and FTD but not healthy controls, and a phosphorylated TDP-43 antibody has been suggested in FTD to correspond to brain pathology on autopsy. 37, 38 This raises the possibility that phosphorylated TDP-43 may serve as a surrogate marker for progression or disease state in ALS, and may be measurable in peripheral tissues such as platelets, which represent the cytosolic TDP-43 population. 39, 40 As an exploratory biomarker, platelet TDP-43 was measured from ALS patient samples. Platelet cytosolic samples were analyzed using a high-throughput capillary electrophoresis-based system (SimpleWestern; ProteinSimple, San Jose, California). The samples were analyzed with anti-TDP-43 (total) and phosphorylated TDP-43 p(S409/410) antibodies (Proteintech, Chicago, Illinois) that crosslinked to the capillaries. Fluorescence-labeled proteins were eluted and intensities were measured. Predictive phosphorylation value (PPV) was calculated by p(S409/410) TDP-43 arbitrary units per total TDP-43 arbitrary units. 36, 39 Randomization and Blinding. Participants were randomly assigned to rasagiline or placebo at a 3:1 ratio, stratified by riluzole use and bulbar onset (yes/no). Randomization was performed centrally utilizing a computer-generated block structure (4 groups based on stratification, in blocks of 4). Study investigators, evaluators, and participants were blinded to treatment assignment.
Sample Size. To increase efficiency, we enriched our placebo cohort with historical placebo controls from clinical trials of minocycline. 41, 42 For the primary outcome only we included the subset of subjects within the historical placebo database with disease durations of <2 years and baseline FVC ≥75%. This cohort had a mean decline on the ALSFRS-R of 1 unit per month. With 80 subjects, 20 placebo (augmented with 177 placebo participants from a previous randomized, controlled trial of minocycline) and 60 treated, we estimated an 80% power (at two-sided 5% level of significance) to detect a treatment response where there is a ≥30% reduction in the ALSFRS-R slope of decline. The power calculations were based on 1,000 simulations, where the slopes for a random subset of 60 placebo patients from our placebo database were reduced by 30% and then compared with the remaining placebos using the same linear mixed effects (LME) model as was used in the current trial. 43 Statistical Analysis. Descriptive statistics (mean and SD, or median with minimum and maximum) were used to describe the study population and adverse-event frequencies. Balanced randomization was tested using a 3-group analysis of variance (ANOVA). For the primary outcome (ALSFRS-R slope of decline) we fit an LME model to the data from each patient. The model for each fit is given by the equation: Y ij = (B0 + b0 i ) + (B1 + B2 * dose(i) + b1 i ) * t ij + e ij , where Y ij is the ALSFRS-R score for the ith patient at time t ij ; dose(i) is zero for placebo and 1 for rasagiline; B0, B1, and B2 are fixed effects for initial value, slope, and slope change due to drug, respectively; and b0 i , b1 i , and e ij are random effects for initial value, slope, and within-patient variation, respectively. All participant data were used, regardless of length of follow-up. The model is self-weighting so that patients with longer follow-up had greater influence on parameter estimates than patients with shorter follow-up. 43 Additional terms were added to the model to adjust for effects of cofactors that differed significantly between the treated, controls, and historical controls (riluzole use, symptom duration). The test for efficacy was based on hypothesis testing, H 0 : B2 = 0, where B2 is the parameter for the change in the slope of ALSFRS-R over time due to rasagiline. The same LME model was used for secondary outcomes (vital capacity and quality of life). For the ALSFRS-R, each data set was fit separately: first, only data from the 80 subjects in the trial were used, then the 80-subject group was augmented with data from historical placebo controls. Death from any cause or tracheostomy were considered survival endpoints. Kaplan-Meier curves were created to compare survival, and the two-sided log-rank test was used to test equality of survival time. 42 The blood and urine mitochondrial biomarker assays were analyzed by paired Student's t-test. The effect of rasagiline on these measures was tested using an LME described previously. For quality assurance, we used plots of individual measurements vs. time to detect outlier values for ALSFRS-R, FVC, QOL, and biomarkers. Any measurement that was beyond 3 standard deviations from the best fitted value (from the LME model) was flagged and rechecked for accuracy by the participant's institution. All statistical testing was two-sided, and P < 0.05 was considered significant. Statistical analysis was performed using Stata version 12 (StataCorp, LLC, College Station, Texas).
RESULTS
One hundred three individuals were screened for eligibility, and 80 were randomized, 60 to rasagiline and 20 to placebo (Fig. 1 ). Reasons for screen failure included failure to meet the inclusion criteria and declining to participate. Thirty individuals discontinued the study (60% from placebo, compared with 30% rasagiline), most commonly due to adverse events. There was 1 death in the placebo group (5%) and 8 deaths in the rasagiline group (13.3%, not statistically significant). No subject met mortality criteria due to need for invasive mechanical ventilation. All 80 participants were included in the intention-to-treat analysis. FIGURE 1. Study flow diagram. One hundred three individuals were assessed for eligibility and 80 were randomized in a 3:1 ratio. Deaths were similar between groups. The placebo group was enriched with historical placebo controls from completed minocycline clinical trials.
41,42
Participants were mostly male, middle-aged, and with limb-onset ( Table 1) . Compared with historical placebo controls, study participants were more likely to be taking riluzole, and had a longer symptom duration.
Outcomes and Measures. Rasagiline did not slow the rate of disease progression compared with placebo as measured by the ALSFRS-R, slow vital capacity, or ALSQOL ( Table 2 ). The 20% difference in the ALSFRS-R slope of decline between rasagiline and placebo was further attenuated on augmenting the placebo group with historical controls, which reinforced the initial impression of no clinical benefit on disease progression (Tables 3 and 4 ).
An adjusted analysis for baseline differences between study participants and historical placebo controls (riluzole use and symptom duration) did not affect the estimates of treatment effects of rasagiline on ALSFRS-R slope of decline (Table 4) .
Rasagiline provided no benefit with regard to survival compared with placebo participants or to historical placebo controls ( Fig. 2A) . We did not see any consistent trend in blood biomarker change, either between baseline and 6-month follow-up or between rasagiline and placebo (Fig. 2B , and Table S3 in the Supplementary Material online). We saw no rasagiline-related difference in urine IsoP or platelet TDP-43 predicted phosphorylation value; however, both rasagiline and placebo groups had decreased predicted TDP-43 phosphorylation over 1 year.
Harms. There were no treatment-related severe adverse events. The most frequent adverse events were gastrointestinal disturbances, followed by musculoskeletal problems, both more frequent in the placebo group (see Table S4 in the Supplementary Material online).
DISCUSSION
Rasagiline did not slow the rate of functional decline in this study and showed no evidence for biomarker engagement. We encountered an unanticipated high rate of discontinuations from the study. However, when evaluating the reasons for discontinuation, no clear explanation emerges (e.g., more adverse events in one group). When comparing this study with the minocycline randomized, controlled trials from which the historical controls were obtained, we identified an overall increased studywide discontinuation rate (37.5% vs. 8%). The statistical analysis counted all available data, creating slopes of decline for each participant. To some degree this adjusts for the problem of missing data, assuming the relative rates of discontinuation were equal across the study timeline and treatment groups. In addition, many decisions went into the study design, including: use of historical controls to increase the study power; the choice to power the study for a 30% difference in ALSFRS-R slope of decline; and use of peripheral mitochondrial and other molecular biomarkers to show drug-target engagement.
This study utilized a screening study design that enriched our placebo group with historical placebo controls to increase power. 7 This decision was based on the observation that, in aggregate, the rates of decline in the ALSFRS-R have been fairly constant across studies with similar inclusion criteria. 7 WALS has an extensive historical placebo control database from which to obtain data and, more recently, large data sets, such as the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database, have become available. 44 The decision to use a screening study design is based on an assumption that, if negative, the likelihood of any meaningful benefit is statistically quite small. 45 Several assumptions underlie the use of historical controls. The first assumption is that matching for basic inclusion and exclusion criteria will yield similar groups. Herein we found differences in the frequency of riluzole use and time from symptom onset, which required adjustment in an ancillary analysis. A second assumption is that, given similar inclusion and exclusion criteria, rates of functional decline on the ALSFRS-R will be consistent. Indeed, there were no significant differences in rates of functional decline between our placebo group and historical controls. Thus, although, in aggregate, the slope in decline on the ALSFRS-R appears to have been fairly constant, which would support our study design, more recent modeling with PRO-ACT showed the group with symptom duration <2 years and FVC > 75% is actually quite diverse, and splits into those with rapid and slow progress. 46 The strongest driver for this is time since symptom onsetand, although there was a difference in time from symptom onset between study participants and historical controls, the adjusted analysis confirms our primary analysis. Although it is likely that a study such as this rules out a major benefit for rasagiline, more sophisticated strategies for historical control matching, a run-in period to stratify into fast and slow progressers, and trial simulation could increase the power of such screening studies. 47 Finally, the recent approval of edaravone may limit the ability to use such historical data sets, as the current standard of care would include edaravone, which may affect disease progression. 2 Although differences in slope of progression of >20% are generally considered to be clinically meaningful, the ALSFRS-R documents the decline of our basic activities of daily living and, as such, much smaller changes projected over time would likely be meaningful to ALS patients. 24 Herein we chose a 30% threshold as we thought the role of such a screening trial should be to select for drugs with potential robust effects: the desired effect of a 30% reduction in slope is roughly equivalent to a 4-6-month life extension (the effect measured for taking riluzole).
Mitochondrial pathology appears to be a consistent finding in ALS-in both autopsy tissues and in animal models. 21, 48 Many heritable ALS mutations are in genes that affect mitochondrial function. Oxidative changes are also a common downstream event. The assays we used here and in our earlier study have the advantage of being commercially available. The decision to use peripheral markers, such as from lymphocytes, platelets, or urine, would only indirectly reflect activity in the central nervous system. In our earlier study we used a combination of established biomarkers for oxidative stress (i.e., ORAC), but also more exploratory assays (annexin, mitotracker, JC-1, and Bcl/Bax) that are used in cell culture experiments in basic science laboratories; our intention was to treat participant blood samples as if they are a "cell culture." Indeed, in our earlier study we observed consistent shifts in lymphocyte biomarker values, suggesting a potentially beneficial effect of rasagiline, on the mitochondrial membrane potential, oxidative stress, or apoptosis markers. Herein we saw higher variability than anticipated, based on results from our previous study, and did not see consistent trends in the rasagiline group when comparing baseline and 6 months, or between rasagiline and placebo. The possibilities for the difference in biomarker findings between the studies include: higher than anticipated variability; differences in wait-time before processing for samples from different sites; need for better strategies in handling outlier data; and the possibility that the original observations were erroneous.
Platelet TDP-43 is an exploratory biomarker and, although there were shifts in both treated and placebo groups toward lower values, it is not clear what this means for the overall utility of platelet TDP-43 as a biomarker. Although it is possible this would reflect a reduction in the phosphorylated TDP-43 population, it is also possible this reflects an increase in total TDP-43. Limitations to our current study include its small sample size-to definitively answer the question of whether there is a small benefit with rasagiline would require a much larger study. In addition, the participants recruited for this study may or may not have reflected ALS patients in the general population. Additional limitations include incomplete matching of baseline characteristics between our study participants and historical controls. Finally, only 50 participants completed the study, so incomplete data may have affected estimates if some unknown factor contributed to individuals exiting the study, and this was different between groups.
We found that rasagiline was well tolerated but we were unable to detect a 30% improvement in the rate of functional decline. The recently completed randomized, controlled study of rasagiline in Germany also did not meet its primary endpoint of survival benefit; however, a post hoc analysis was able to discern approximately 40% slowing of functional loss in the half of participants who were most rapidly progressing. 49 This is in line with a study with edaravone, which also employed a strategy to select more rapidly progressing participants. Thus, in the future, for drugs that may provide a protective benefit, an inclusion strategy that selects for normal to rapid progressers may reduce the overall variability and improve the power to detect a small benefit on functional decline compared with standard practice. Such an approach could also be used with studies that utilize historical controls. The same selection using rates of progression could be applied to historical placebo data sets, assuming such data sets including edaravone become available. The main limitation may be to trial generalizability, because such approaches raise the question of whether these benefits in more rapidly progressing participants early in the disease course will persist or accrue in patients with longer disease courses or much slower rates of functional loss.
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